Catalyst Dossier · compiled by CeliA 🧫

Chugai Pharmaceutical Co., Ltd. (4519.T)

Biotechnology · market cap $87.4B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-06-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Chugai Pharmaceutical (4519.T) is a large-cap Japanese biotechnology company with a market capitalization of approximately $87.4 billion and roughly 5,026 employees. The company operates a broad pipeline spanning rheumatology, oncology, bone metabolism, hematology, and dermatology, with multiple assets in Phase 2 and Phase 3 across both established and novel mechanisms. The nearest discrete catalyst on record is an estimated Phase 2 data readout for DONQ52 in Celiac Disease, expected around June 2027.

The catalyst path

2027-06-15 (est.)Phase 2 · DONQ52imp 7/10

Pipeline

Asset	Phase	Indication
Paclitaxel	Phase 2	Metastatic Breast Cancer
MTX	Phase 3	Rheumatoid Arthritis
DONQ52	Phase 2	Celiac Disease
ED-71	Phase 3	Osteoporosis
peginterferon alfa-2a	Phase 3	Chronic Hepatitis C
recombinant human erythropoietin	Phase 3	Chemotherapy Induced Anemia
MRA (Tocilizumab)	Phase 3	Rheumatoid Arthritis
ibandronic acid 0.5mg	Phase 3	Primary Osteoporosis
nemolizumab (CIM331)	Phase 2	Atopic Dermatitis
monoclonal antibody CAL	Phase 2	Breast Cancer
Tocilizumab + methotrexate(MTX)	Phase 3	Rheumatoid Arthritis (RA)
peginterferon alfa-2a 180μg	Phase 3	Liver Cirrhosis
Tocilizumab+Methotrexate(MTX)	Phase 3	Rheumatoid Arthritis
GM-611	Phase 2	Gastroparesis
R744	Phase 3	Hemodialysis Patients
MRA(Tocilizumab)	Phase 3	Systemic Juvenile Idiopathic Arthritis
epoetin beta	Phase 3	Anemia
Oxaliplatin	Phase 2	Colorectal Cancer
BO-653	Phase 3	Graft Occlusion, Vascular

Price & technical context

3-month

+26.8%

6-month

+11.6%

12-month

+29.5%

52-wk range

$6011.00–$8620.00

vs 50-day MA

+12.4%

vs 200-day MA

+17.9%

Realized vol

43.9%

Max drawdown

-30.3%

Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for 4519.T (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.